Navigation Links
Watson First Quarter 2011 Net Revenue Increases to $877 Million
Date:4/27/2011

on of forecasted net income for the twelve months ending December 31, 2011 to non-GAAP net income and non-GAAP earnings per diluted share:Table 6WATSON PHARMACEUTICALS, INC.Reconciliation Table - Forecasted Non-GAAP Earnings per Diluted Share(Unaudited; in millions except per share amounts)Forecast for Twelve Months Ending December 31, 2011LowHighGAAP to non-GAAP net income calculationGAAP net income$
227$
258Adjusted for:Amortization276276Global supply chain initiative1515Acquisition and licensing charges 3434Interest accretion on contingent obligations3838Non-cash impairment charges1414Other (gains) losses(6)(6)Income taxes(99)(99)Non-GAAP net income$
499$
530Diluted earnings per shareDiluted earnings per share - GAAP $
.80$
2.04Diluted earnings per share - Non-GAAP$
3.95$
4.20Diluted weighted average common shares outstanding126.3126.3The reconciliation table is based in part on management's estimate of non-GAAP net income for the year ending December 31, 2011.  Watson expects certain known GAAP charges for 2011, as presented in the schedule above.  Other GAAP charges that may be excluded from non-GAAP net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown.  These GAAP charges are dependent upon future events and valuations that have not yet been performed.

The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2011 to adjusted EBITDA:Table 7WATSON PHARMACEUTICALS, INC.Reconciliation Table - Forecasted Adjusted EBITDA(Unaudited; in millions)Forecast for Twelve Months Ending December 31, 2011LowHighGAAP net income$
227$
258Plus:Interest expense8888Interest income(1)(1)Provision for income taxes175194Depreciation (includes accelerated depreciation)102102Amortization276276EBITDA867917Adjusted for:Global supply chain initiative1212Acquisition and licens
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
2. Watson Confirms Welchol® Patent Challenge
3. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
4. Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
5. Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
6. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
7. Watson Confirms OxyContin® Patent Challenge
8. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
9. Cephalon Wins FENTORA Patent Suit Against Watson
10. Watson Launches Generic Famvir®
11. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
(Date:4/23/2014)... scientists led by a researcher from the Cancer Science ... of Singapore has identified the cancer specific stem cell ... possibility of developing new drugs for the treatment of ... research group, led by Dr Chan Shing Leng, Research ... time that a cancer-specific variant of a cell surface ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... few decades researchers have characterized a set of clock ... in all types of species, from flies to humans. ... researchers surmise there are more. A team from the ... wondered if big-data approaches could find them. , ... Hogenesch, PhD, professor of Pharmacology and first author Ron ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... March 18 German medical device,manufacturer Ziehm Imaging ... European Congress of Radiology (ECR) in Vienna. This ... requiring minimal OR space. The,system provides flexible image ... OR monitors. Ziehm Solo was designed to meet ...
... provider of comprehensive medical record solutions for healthcare ... on Wednesday, March 25th at their headquarters in ... Future" will focus on the rollout of the ... meant to promote the integration of electronic medical ...
... 17 The Generic Pharmaceutical Association (GPhA) released the ... Jaeger regarding the introduction of H.R. 1548, "The Pathway ... is the wrong road for patients looking for safe ... times. It is a long route filled with ...
... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, ... Senior Vice President of Government Affairs on the ... Eshoo and Joe Barton: "In this year of ... to affordable medicines. The legislation re-introduced in the ...
... University of Illinois at Chicago College of Medicine have ... protein snarls found in the brains of Alzheimer,s patients ... needed to combat the neurodegenerative disease. , Alzheimer,s disease, ... and is among the most costly diseases to society ...
... WASHINGTON, March 17 A federal jury in Miami ... connection with a $5.3 million Medicare fraud scheme, Acting ... Division and U.S. Attorney R. Alexander Acosta of the ... federal court in Miami, a jury found David Rothman, ...
Cached Medicine News:Health News:Ziehm Imaging Introduces Ziehm Solo C-arm, Featuring a Versatile set-up in the OR and Exceptional Image Quality 2Health News:Ziehm Imaging Introduces Ziehm Solo C-arm, Featuring a Versatile set-up in the OR and Exceptional Image Quality 3Health News:Microwize to Hold Free Stimulus Package Workshop for Medical Industry 2Health News:Microwize to Hold Free Stimulus Package Workshop for Medical Industry 3Health News:GPhA Statement on Introduction of H.R. 1548, 'The Pathway for Biosimilars Act' 2Health News:Mechanism of Alzheimer's suggests combination therapy needed 2Health News:Mechanism of Alzheimer's suggests combination therapy needed 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4